RxDoctor Payments Data

Rajesh Gupta, MD

Neurology · Alexandria, VANPI 1164680674

Payments from drug & device makers

$15,564in general payments, 2019–2025

Across 576 payments — averaging $27.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • Livanova USA, Inc.$2K
  • AbbVie$2K
  • SK Life Science, Inc.$796
  • Supernus Pharmaceuticals, Inc.$721
  • Neuropace, Inc.$620
  • plus $7K from 52 others

What the payments were for

  • Speaking & faculty fees$430%
  • Travel & lodging$1,64811%
  • Food & beverage$13,85089%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.70$2,618
Livanova USA, Inc.17$1,976
AbbVie(2 entities)111$1,831
SK Life Science, Inc.16$796
Supernus Pharmaceuticals, Inc.39$721
Neuropace, Inc.3$620
Lilly USA, LLC26$601
Novartis40$571
Eisai Inc.28$406
Lundbeck LLC16$376
Medtronic(2 entities)5$333
Jazz Pharmaceuticals Inc.15$303
Biogen14$298
Neurelis, Inc.13$287
Amgen11$273
Sanofi15$270
MDD US Operations, LLC4$223
Sunovion Pharmaceuticals Inc.8$216
Harmony Biosciences LLC9$202
Bristol Myers Squibb11$187
Teva Pharmaceuticals USA, Inc.8$183
AstraZeneca8$182
E.r. Squibb & Sons, L.L.C.7$182
Catalyst Pharmaceuticals, Inc.3$178
Upsher-smith Laboratories LLC6$130
Pfizer5$98
Argenx US, Inc.4$95
Biohaven Pharmaceutical Holding Company Ltd.4$94
EMD Serono, Inc.5$93
Bausch Health US, LLC5$90
Sumitomo Pharma America, Inc.2$81
Aucta Pharmaceuticals, Inc.1$80
Almatica Pharma LLC3$73
Neurocrine Biosciences, Inc.3$62
Ironshore Pharmaceuticals Inc.4$60
Acorda Therapeutics, Inc3$59
TG Therapeutics, Inc.2$55
Takeda Pharmaceuticals U.S.A., Inc.2$54
Avanir Pharmaceuticals, Inc.3$52
Biohaven Pharmaceuticals, Inc.3$51
Zogenix Inc.1$49
Merz North America, Inc.1$48
Amneal Pharmaceuticals LLC2$47
Corium, LLC2$36
Assertio Therapeutics, Inc.2$34
Shire North American Group Inc2$31
Idorsia Pharmaceuticals US Inc2$31
Abbott1$28
Currax Pharmaceuticals LLC2$28
Merz Pharmaceuticals, LLC1$28
Scilex Pharmaceuticals Inc.1$22
IBSA Pharma Inc.1$20
Tanabe Pharma America, Inc.1$20
Vanda Pharmaceuticals Inc.1$19
Promius Pharma LLC1$19
Adamas Pharmaceuticals, Inc.1$18
Otsuka America Pharmaceutical, Inc.1$14
Braintree Laboratories, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,564 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$196,010
Medicare patients
538
Services billed
3,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe34$29,717
AptiomEslicarbazepine Acetate13$29,136
ValtocoDiazepam15$24,105
NayzilamMidazolam14$19,237
Emgality PenGalcanezumab-Gnlm21$17,579
NuedextaDextromethorphan Hbr/Quinidine12$17,059
QuliptaAtogepant12$15,048
Levetiracetam209$5,020
Lacosamide60$4,588
Memantine Hcl157$4,254
Duloxetine Hcl175$3,083
Gabapentin243$2,995
Donepezil Hcl254$2,654
Carbamazepine ErCarbamazepine34$1,910
Divalproex Sodium49$1,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$216$29,13613 claims
Neurelis, Inc.Valtoco$287$24,10515 claims
UCB, Inc.Nayzilam$2,618$19,23714 claims
Avanir Pharmaceuticals, Inc.Nuedexta$52$17,05912 claims
AbbVieQulipta$1,831$15,04812 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$47$1,19031 claims
Almatica Pharma LLCSertraline Hcl$73$1,154118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 neurology providers in Virginia.

Other neurology in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →